FindMyKOL
Clinical trialNCT01808456CompletedPhase 4Interventional

Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.

NCT01808456 is a phase 4 interventional trial sponsored by Inova Health Care Services. As of 21 Nov 2026, it is completed. It studies Influenza trivalent inactive vaccine and Influenza trivalent inactive vaccine high dose in Influenza, Human and Transplantation Infection. The registry lists an enrollment of 62 participants at 1 site in 1 country. The registry lists a start date of 31 Oct 2013 and a primary completion date of 31 Dec 2016.

SponsorInova Health Care Services →Enrollment62Influenza, HumanTransplantation Infection
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01808456
FieldValue
Registry IDNCT01808456
StatusCompleted
PhasePhase 4
Study typeInterventional trial
Lead sponsorInova Health Care Services
Enrollment62
Registered sites1
Countries1
ConditionsInfluenza, Human and Transplantation Infection
DrugsInfluenza trivalent inactive vaccine and Influenza trivalent inactive vaccine high dose
Start31 Oct 2013
Primary completion31 Dec 2016
Study completion31 Dec 2016
Last update posted22 Jul 2022

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Influenza infection in recipients of solid organ transplants recipients while on maintenance immunosuppressant therapy is associated with increased morbidity and mortality. Although influenza vaccination is recommended in these high-risk patients, safety and immunogenicity of commercially available different strengths of influenza vaccine have not been established. The primary study objective is to determine the safety and immunogenicity of Fluzone and Fluzone High-Dose, with a secondary objective to determine the tolerability and efficacy of two different strengths of trivalent influenza vaccine (TIV, flu vaccine). Both vaccines are commercially available for use in the general population. Fluzone is approved for use in 6 months of age and older, and Fluzone High-Dose is approved for use in 65 years of age and older. This is an exploratory, open-label, parallel group, observer blinded, prospective study. All recipients of kidney, lung, heart transplants who attend for post-transplant follow-up, at least 30-days after transplantation at Inova Fairfax Hospital Transplant Center will be eligible for enrollment. Enrolled patients will be followed for three months (a total of 4 visits) following enrollment and randomization: day 0 (enrollment) and follow-up visits at weeks 1, 4, 8, and 12.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Virginia, United States1 site
  • Inova Fairfax Hospital

    Falls Church

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginia: 1 siteVA1MarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Influenza trivalent inactive vaccineInfluenza trivalent inactive vaccine high dose
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT01808456

Each answer restates registry values shown on this page.

What is NCT01808456?

NCT01808456 is a phase 4 interventional trial sponsored by Inova Health Care Services. It studies Influenza trivalent inactive vaccine and Influenza trivalent inactive vaccine high dose in Influenza, Human and Transplantation Infection.

Who leads NCT01808456?

The registry names Ravinder Wali, MD (principal investigator, Inova Fairfax Hospital) as the overall official.

Where does NCT01808456 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT01808456 study?

The registered drug and biological interventions are Influenza trivalent inactive vaccine and Influenza trivalent inactive vaccine high dose.

When did NCT01808456 end?

The registry lists a primary completion date of 31 Dec 2016 and a study completion date of 31 Dec 2016. The sponsor last updated the record on 22 Jul 2022.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.